Abstracts tagged "Autoantibody(ies)"

Abstract Number: 0707 • ACR Convergence 2021
Association of Pneumomediastinum with Poor Prognosis in Patients with Myositis-Associated Interstitial Lung Disease
Kazuki Hirano¹, Azusa Kojima¹, Akira Ishii¹, Mai Sugiyama¹, Yuto Izumi¹, Noriko Sasaki², Yuji Hosono¹, Chiho Yamada¹ and Shinji Sato³, ¹Tokai University School of Medicine, Isehara, Japan, ²tokai university, sagamihara-city, Japan, ³Tokai University, Isehara, Japan
Background/Purpose: Pneumomediastinum is an important complication in patients with myositis-associated interstitial lung disease (ILD). Patients with myositis and ILD who had pneumomediastinum during the disease…
Abstract Number: 1481 • ACR Convergence 2021
Malondialdehyde-acetaldehyde Antibodies Occur in Systemic Lupus Erythematosus and Associate Specifically with Neuropsychiatric Involvement
Rory Monahan, Michelle van Beukel, Nicole Borggreven, Margreet Kloppenburg, Tom WJ Huizinga, Gerda Steup-Beekman and Leendert Trouw, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogenous autoimmune disease characterized by a global loss of self-tolerance. Although autoantibodies are an important hallmark of SLE,…
Abstract Number: 1932 • ACR Convergence 2021
Identifying Clusters of Longitudinal Autoantibody Profiles Associated with Systemic Lupus Erythematosus Disease Outcomes
May Choi¹, Irene Chen², Ann Clarke³, Marvin Fritzler³, Katherine Buhler³, Murray Urowitz⁴, John Hanly⁵, Caroline Gordon⁶, Yvan St.Pierre⁷, Sang-Cheol Bae⁸, Juanita Romero-Diaz⁹, Francisco Sanchez-Guerrero¹⁰, Sasha Bernatsky¹¹, Daniel Wallace¹², David Isenberg¹³, Anisur Rahman¹⁴, Joan Merrill¹⁵, Paul R Fortin¹⁶, Dafna Gladman¹⁷, Ian N. Bruce¹⁸, Michelle Petri¹⁹, Ellen Ginzler²⁰, Mary Anne Dooley²¹, Rosalind Ramsey-Goldman²², Susan Manzi²³, Andreas Jnsen²⁴, Graciela Alarcn²⁵, Ronald van Vollenhoven²⁶, Cynthia Aranow²⁷, Meggan Mackay²⁷, Guillermo Ruiz-Irastorza²⁸, S Sam Lim²⁹, Murat Inanc³⁰, Kenneth Kalunian³¹, Sren Jacobsen³², Christine Peschken³³, Diane Kamen³⁴, Anca Askanase³⁵, David Sontag² and Karen Costenbader³⁶, ¹Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ²Massachusetts Institute of Technology, Cambridge, MA, ³University of Calgary, Calgary, AB, Canada, ⁴Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ⁵Dalhousie University, Halifax, NS, Canada, ⁶Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁷Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁸Hanyang University Medical Center, Seoul, Republic of Korea, ⁹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Federal District, Mexico, ¹⁰University Health Network/Sinai Health system, Toronto, ON, Canada, ¹¹McGill University, Montréal, QC, Canada, ¹²Cedars-Sinai, Los Angeles, CA, ¹³Centre for Rheumatology, University College London, London, United Kingdom, ¹⁴University College London, London, United Kingdom, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹⁷Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ¹⁸University of Manchester, Manchester, United Kingdom, ¹⁹Johns Hopkins University School of Medicine, Baltimore, MD, ²⁰SUNY Downstate Health Sciences University, Brooklyn, NY, ²¹Raleigh Neurology Associates, Chapel Hill, NC, ²²Northwestern University, Chicago, IL, ²³Allegheny Health Network, Wexford, PA, ²⁴Lund University, Lund, Sweden, ²⁵University of Alabama at Birmingham, Birmingham, AL, ²⁶Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ²⁷Feinstein Institutes for Medical Research, Manhasset, NY, ²⁸Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain, ²⁹Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ³⁰Istanbul University Faculty of Medicine, Istanbul, Turkey, ³¹UC San Diego, La Jolla, CA, ³²Copenhagen Lupus and Vasculitis Clinic, Centre for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ³³University of Manitoba, Winnipeg, MB, Canada, ³⁴Medical University of South Carolina, Charleston, SC, ³⁵Columbia University Medical Center, New York, NY, ³⁶Brigham and Women's Hospital, Belmont, MA
Background/Purpose: Prior studies of SLE clusters based on autoantibodies have utilized cross-sectional data from single centers. We applied clustering techniques to longitudinal and comprehensive autoantibody…
Abstract Number: 0032 • ACR Convergence 2021
IL-40: A New B-cell Associated Cytokine Up-regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates with Disease Activity, Autoantibodies and NETosis
Adela Navratilova¹, Lucie Andrés Cerezo¹, Hana Hulejová², Viktor Bečvář², Michal Tomcik³, Dana Tegzova², Martina Olejárová¹, David Veigl⁴, Karel Pavelka³, Jiri Vencovsky² and Ladislav Senolt³, ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴First Orthopaedic Clinic, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Interleukin 40 (IL-40) is recently identified B cell - associated cytokine implicated in humoral immune responses and in B cell development and homeostasis. As…
Abstract Number: 0306 • ACR Convergence 2021
Allergic Disorders in Primary Sjögren’s Syndrome Compared with Rheumatoid Arthritis
Misako Higashida-Konishi¹, Keisuke Izumi², Tatsuya Shimada³, Satoshi Hama⁴, Mitsuhiro Akiyama⁵, Hisaji Oshima⁴ and Yutaka Okano⁶, ¹Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Meguroku, Japan, ²Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center/Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center/ Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, ⁴Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, tokyo, Japan, ⁵Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center/ Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Palo Alto, CA, ⁶Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Kawasaki, Japan
Background/Purpose: Allergic disorders are occasionally seen in patients with primary Sjögren's syndrome (pSS) [1]. Risk factors are unclear for allergic disorders.We aimed to compare the…
Abstract Number: 0713 • ACR Convergence 2021
MDA5 Helicase Domains Identified as the Main Targets of Anti-MDA5 Autoantibodies in European Dermatomyositis Patients
Eveline Van Gompel¹, Catia Cerqueira², Karine Chemin³, Begum Horuluoglu¹, Angeles Shunashy Galindo-Feria⁴, khaled amara⁵, Edvard Wigren⁶, Susanne Gräslund⁶, Ellen De Langhe⁷, Olivier Benveniste⁸ and Ingrid E Lundberg⁶, ¹Karolinska Institutet, Stockholm, Sweden, ²4Dcell, Montreuil, France, ³Division of Rheumatology, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁵Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁶Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden, ⁷KU Leuven, Leuven, Belgium, ⁸UPMC, Paris, France
Background/Purpose: The presence of anti-melanoma differentiation associated protein 5 (MDA5) autoantibodies in myositis patients is associated with mucocutaneous ulcerations, (rapidly progressing) interstitial lung disease (RPILD),…
Abstract Number: 1489 • ACR Convergence 2021
Identification of Mitochondrial Antigens Targeted by Autoantibodies in Systemic Lupus Erythematosus (SLE)
Yann BECKER¹, Jean-Philippe Gagné², Anne-Sophie Julien³, Tania Lévesque¹, Nadine Gougeard⁴, Vicente Rubio⁴, François-Michel Boisvert⁵, Dominique Jean⁶, Guy Poirier², Paul R Fortin⁷ and Éric Boilard¹, ¹Centre de Recherche ARThrite, Université Laval, Québec City, QC, Canada, ²Centre de Recherche du Centre Hospitalier Universitaire de Québec - Université Laval, Québec City, QC, Canada, ³Département de mathématiques et statistique, Université Laval, Québec, QC, Canada, ⁴Structural Enzymopathology Unit, Instituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Científicas, Valencia, Spain, ⁵Department of Anatomy and Cell Biology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶Department of Anatomy and Cell Biology, Université de Sherbrooke, Sherbrooke, Canada, ⁷CHU de Quebec - Universite Laval, Québec City, QC, Canada
Background/Purpose: Mitochondria are organelles that possess several bacterial features such as a double-stranded genome with hypomethylated CpG islets, formylated proteins, and a double membrane composed…
Abstract Number: 0037 • ACR Convergence 2021
Identification and Validation of Four Circulating Autoantibodies Associated with the ACPA Status in Early Rheumatoid Arthritis
Lucía Lourido¹, Cristina Ruiz-Romero², Lidia Collado¹, Monika Hansson³, Lars Klareskog⁴, Ronald Sjöberg⁵, Elisa Pin⁵, Peter Nilsson⁵ and Francisco Blanco-García⁶, ¹Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España., A Coruña, Spain, ²Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España.Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN). Av. Monforte de Lemos, 3-5. Pabellón 11, 28029, Madrid, España., A Coruña, Spain, ³Division for Rheumatology, Karolinska Institutet, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁵Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology & SciLifeLab, Stockholm, Sweden, ⁶Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España.Universidade da Coruña (UDC), Grupo de Investigación de Reumatología y Salud (GIR-S). Departamento de Fisioterapia, Medicina y Ciencias Biomédicas, Facultad de Fisioterapia, Campus de Oza, 15008, A Coruña, España., A Coruña, Spain
Background/Purpose: The presence of anti-citrullinated protein antibodies (ACPAs) is a highly specific hallmark of rheumatoid arthritis (RA), that is present also in early disease. However,…
Abstract Number: 0323 • ACR Convergence 2021
Ro Positivity Is an Under‐Recognised Poor Prognostic Marker in Systemic Lupus Erythematosus Patients
Katie Liao¹, Thilinie De Silva¹, Julie Bonin², Rachel Koelmeyer² and Alberta Hoi³, ¹Department of Rheumatology, Monash Health, Melbourne, Australia, ²Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia, ³Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia
Background/Purpose: Antibodies to Ro60 (SSA) or Ro52 (SSB) have been described as one of the defining autoantibodies in Sjogren syndrome but they are also commonly…
Abstract Number: 0720 • ACR Convergence 2021
The Clinical Significance of anti-PC4 and SFRS1 Interacting Protein 1 Antibody in Polymyositis and Dermatomyositis Patients
Yuji Hosono¹, Azusa Kojima¹, Akira Ishii¹, Yuto Izumi¹, Kazuki Hirano¹, Noriko Sasaki², Chiho Yamada¹ and Shinji Sato³, ¹Tokai University School of Medicine, Isehara, Japan, ²tokai university, sagamihara-city, Japan, ³Tokai University, Isehara, Japan
Background/Purpose: Many kinds of myositis specific autoantibodies are detected in sera from polymyositis (PM) and dermatomyositis (DM). Screening for autoantibodies is essential in the diagnostic…
Abstract Number: 1490 • ACR Convergence 2021
Myeloid and B Cell Transcriptional Phenotypes Reveal Race Dependent Differences in Early Autoimmunity
Aleksandra Bylinska, Samantha Slight-Webb, Kevin Thomas, Miles Smith, Susan Macwana, Nicolas Dominguez, Eliza Chakravarty, Joan Merrill, Judith James and Joel Guthridge, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Early immune events leading to clinical autoimmune disease are complex and the pathways involved remain incompletely defined. Anti-nuclear antibody (ANA) positivity is a feature…
Abstract Number: 0044 • ACR Convergence 2021
Autoantibodies Against Malondialdehyde-modifications Promote Osteoclast Development by Reprogramming Cellular Metabolism
Koji Sakuraba¹, Akilan Krishnamurthy¹, Alexandra Circiumaru², Jitong Sun¹, Vijay Joshua¹, Heidi Wähämaa¹, Marianne Engström¹, Meng Sun¹, Xiaowei Zheng¹, Cheng Xu¹, khaled amara¹, Vivianne Malmström¹, Sergiu Catrina¹, Caroline Grönwall¹, Anca Catrina¹ and Bence Réthi¹, ¹Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ²Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden
Background/Purpose: Malondialdehyde (MDA) is a highly reactive compound generated during lipid-peroxidation in conditions associated with oxidative stress. MDA can irreversibly modify proteins (e.g. lysine, arginine…
Abstract Number: 0330 • ACR Convergence 2021
Serologic Phenotypes Distinguish SLE Patients with Myositis And/or Interstitial Lung Disease (ILD)
Thaisa Cotton¹, Marvin Fritzler², May Choi³, Boyang Zheng⁴, Omid Zahedi Niaki⁵, Louis-Pierre Grenier⁵, Evelyne Vinet⁶, Christian Pineau¹, Luck Lukusa⁷, Fares Kalache⁵ and Sasha Bernatsky¹, ¹McGill University, Montréal, QC, Canada, ²University of Calgary, Calgary, AB, Canada, ³Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵McGill University Health Centre, Montréal, QC, Canada, ⁶McGill University Health Centre, Mont Royal, QC, Canada, ⁷Research Institute of the McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: To determine if a serologic phenotype can be identified in SLE patients with myositis and/or ILD.Methods: Adult SLE patients (without myositis or ILD at…
Abstract Number: 0858 • ACR Convergence 2021
Effect of COVID Infection and COVID Vaccination on SLE Activity, Including Antiphospholipid Antibodies
Michelle Petri¹, Jessica Li² and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: SLE patients may have a particular propensity to some viral infections including zoster and CMV. International studies have suggested that prednisone and rituximab may…
Abstract Number: 1492 • ACR Convergence 2021
A Permissive Factor of Anti-Ro+ Mothers of Neonatal Lupus Children Is Linked to Overt SLE Associated with Immunity to a Gut Commensal
Robert Clancy¹, Miranda Marion², Hannah Ainsworth², Miao Chang¹, Timothy Howard³, Peter Izmirly⁴, Mala Masson⁵, Jill Buyon⁶ and Carl Langefeld⁷, ¹NYU Grossman School of Medicine, New York, NY, ²Wake Forest University, Winston-Salem, NC, ³Wake Forest University, Quakertown, NC, ⁴New York University School of Medicine, New York, NY, ⁵NYU Grossman School Medicine, New York, NY, ⁶NYU School of Medicine, New York, NY, ⁷Wake Forest University, Winston Salem, NC
Background/Purpose: Unknown factors trigger the transition of anti-Ro+ mothers of neonatal lupus (NL) children from preclinical autoimmunity to clinical disease. One candidate may be the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].